AstraZeneca, Ikena Team Up Against EGFR-mutated NSCLC 0 18.10.2022 03:00 Feedity.com Ikena Oncology and AstraZeneca have entered into an agreement to evaluate Tagrisso (osimertinib) with Ikena's IK-930 in EGFR-mutated non-small cell lung cancer. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
